castrate-resistant metastatic prostate cancer

March 11, 2019

Zejula Cuts Tumor Burden in Significant Proportion of Advanced PC Patients

News

Four in 10 adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA mutations respond to treatment with Zejula (niraparib), according to early results of an ongoing Phase 2 trial. The GALAHAD study (NCT02854436), ... Read more

May 19, 2016May 19, 2016

Peripheral Nerve Damage with Prostate Cancer Drug May Be Predicted by a Gene Mutation

News

A specific genetic variant of the VAC14 gene may be involved in the development of peripheral neuropathy following taxane administration, a group of drugs commonly used for breast, ovary, lung, ... Read more